- Company
- Zolgensma, which is the same price as an apartment
- by Moon, sung-ho Sep 8, 2022 05:58am
- With ultra-high-priced treatments from global pharmaceutical companies newly entering the benefit range this year, human "risk management" is emerging as an issue at clinical sites. Since the treatment is so expensive, "risk" management issues such as damage and loss that may occur during administration are acting as a key issue. Kymriah,
- Company
- Godex’s price to be cut further under PVA
- by Nho, Byung Chul Sep 7, 2022 05:52am
- Celltrion Pharm’s liver disease treatment Godex cap. is experiencing ‘double trouble,’ being subject to Price-Volume Agreement negotiations after reimbursement reevaluations. According to industry sources, Godex’s price will be cut by &8361;15 per capsule (4% reduction) from &8361;371 to &8361;356 as of the 1st of this month.
- Company
- Poziotinib responds 100% to pts with lung cancer mutations
- by Sep 7, 2022 05:52am
- Poziotinib, a new lung cancer drug exported by Hanmi Pharmaceutical, was found to have a significant effect on the G778 mutation, which is common in patients with HER2 Exxon20 insertion mutation. As a result of ZENITH20 clinical subanalysis, 12 patients showed 100% response, and PFS was also longer than other HER2 Exxon20 mutants. In particul
- Company
- Kisqali’s sales surge, Ibrance’s sales falter
- by Sep 6, 2022 05:51am
- Competition for breast cancer-treating cyclin-dependent kinases (CDK) 4/6 inhibitors in the market are heating up. Kisqali, which was the last to enter the market, has grown rapidly in the first half of this year and exceeded sales of the runner-up product in the market, Verzenio. Ibrance, the sole leader in the market, has also seen a dow
- Company
- Prevenar 13 set to make ₩40B this year
- by Nho, Byung Chul Sep 5, 2022 05:55am
- Pfizer’s Prevenar 13 was found to be maintaining its overwhelming 70% share in the pneumococcal vaccine market. According to its distribution & shipment performance data, sales of Prevenar 13 in 1H this year reached &8361;19.4 billion, and its annual sales are expected to exceed that of the &8361;38.1 made last year. In terms of
- Company
- What are the chances of Dovprela's successful benefits?
- by Eo, Yun-Ho Sep 5, 2022 05:55am
- Attention is focusing on whether the new tuberculosis drug Dovprela, which appeared in 50 years, can be listed on the insurance benefit list. According to related industries, Viatris Korea's Dovprela passed the HIRA Pharmaceutical Benefit Evaluation Committee on the 1st. Dovprela, which was approved in Korea in October last year after U.S.
- Company
- It has been a year since the release of Leclaza
- by Chon, Seung-Hyun Sep 5, 2022 05:55am
- Korea's first new anti-cancer drug is expected to generate 10 billion won in annual sales. Leclaza, a new anti-cancer drug developed by Yuhan Corporation, surpassed 10 billion won in cumulative sales within a year of its release in Korea. It showed a smooth move in the early stages of its release and predicted that it would surpass 10 billion
- Company
- Vyndamax is finally a step towards benefits
- by Eo, Yun-Ho Sep 2, 2022 06:03am
- Transthyretin cardiomyopathy new drug Vyndamax has finally made progress. According to related industries, Vyndamax, a treatment for ATTR-CM (ATTR amyloidosis with cardiomyopathy) caused by Transthyretin amyloidosis in Pfizer, recently passed the HIRA Pharmaceutical Benefit Standards Subcommittee. This is the result of his fourth attempt. As
- Company
- Q2 sales of Nexavar and Lenvima both sluggish
- by Kim, Jin-Gu Sep 2, 2022 06:03am
- Sales of all major liver cancer treatments are on the decline. Sales of Nexavar (sorafenib), which had dominated the first-line treatment market for liver cancer for over a decade, is on a continuous decline since the entry of its generics, and sales of Nexavar’s main competitor Lenvima have also been shown to be slowing down recently
- Company
- Japan first approved AZ Evusheld as Coronavirus tx
- by Sep 2, 2022 06:02am
- Japan approved AstraZeneca's long-lasting antibody complex Evusheld for the first time in the world for COVID-19 treatment. On the 30th (local time), Ministry of Health, Labour and Welfare of Japan approved the Evusheld as a prevention of symptomatic diseases caused by COVID-19 infection (pre-exposure prophylactic therapy) and a treatment for
